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Abstract
Background: Whole-cell phenotypic screening is the driving force behind modern 
anti-tubercular drug discovery efforts. Focus has shifted from screening for bacteri-
cidal scaffolds to screens incorporating target deconvolution. Target-based screening 
aims to direct drug discovery toward known effective targets and avoid investing re-
sources into unproductive lines of enquiry. The protein synthesis pipeline, including 
RNA polymerase and the ribosome, is a clinically proven target in Mycobacterium 
tuberculosis. Screening for new hits of this effective target pathway is an invaluable 
tool in the drug discovery arsenal.
Methods: Using M. tuberculosis H37Rv augmented with anhydrotetracycline-in-
ducible expression of mCherry, a phenotypic screen was developed for the identifi-
cation of protein synthesis inhibitors in a medium throughput screening format.
Results: The assay was validated using known inhibitors of protein synthesis to 
show a dose-dependent reduction in mCherry fluorescence. This was expanded to 
a proprietary screen of hypothetical protein synthesis hits and modified to include 
quantitative viability measurement of cells using resazurin.
Conclusion: Following the success of the proprietary screen, a larger scale screen of 
the GlaxoSmithKline anti-tubercular library containing 2799 compounds was con-
ducted. Combined single shot and dose-response screening yielded 18 hits, 0.64% of 
all screened compounds.
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1 |  INTRODUCTION
Mycobacterium tuberculosis, the causative agent of tuberculo-
sis (TB), remains one of the most successful bacterial patho-
gens. Despite extensive international co-operation TB remains 
extremely difficult to treat and has a high mortality rate, with 
an estimated 10.4 million new cases and over 1.7 million deaths 
in 2016 alone.1 The long duration and unpleasant side effects 
of TB treatment regimens results in poor patient compliance 
that together with global overuse of antibiotics have contributed 
to the rise of multidrug resistant (MDR) and extensively drug 
resistant (XDR) strains of M. tuberculosis. In 2016, there were 
approximately 600  000 rifampicin and MDR TB new cases, 
leading to 240 000 deaths worldwide.2 In order to address the 
need for new antimicrobials and help combat the rising issue of 
antibiotic resistance, drugs with novel modes of action against 
clinically proven targets need to be identified.
The protein synthesis pipeline, containing RNA polymerase 
(RNAP), approximately 22 tRNA synthases,3 and the ribosome 
represents one of the most crucial aspects of biological life. 
Both RNAP and the ribosome have been successfully inhibited 
in M. tuberculosis by rifampicin (RIF)4–8 and streptomycin,9–14 
respectively, drugs that see extensive use in the clinic for treat-
ing TB.15 New scaffolds that target these complexes at different 
sites are an attractive proposition for further drug development 
and clinical use. Recently, Lin et al demonstrated compounds 
that inhibit RNAP at an alternate site to RIF, can be co-admin-
istered, and have a cumulative bactericidal effect resulting in 
suppression of antibiotic resistance generation in M. tuberculo-
sis.16 Several ribosomal inhibitors may also have synergistic ac-
tion when used together. Linezolid, a ribosomal inhibitor with 
unfavorable side effects, has increased bioavailability when 
co-administered with clarithromycin, allowing a reduction in 
dose delivered to patients with MDR-TB.17 In addition, spec-
tinomycin displays a reduced minimum inhibitory concentra-
tion (MIC) in combination with other mycobacterial ribosomal 
inhibitors from the macrolide, tetracycline, and lincosamide 
classes.18,19 While, there are no commercially approved tRNA 
synthase inhibitors for the treatment of TB, several inhibi-
tors have been outlined in the literature.20–23 Specifically, the 
3-aminomethyl compounds containing boron that successfully 
inhibit mycobacterial leucyl-tRNA synthetase,21,22 as well as, 
various inhibitors of aspartyl-tRNA synthetase.20,23
Drug discovery and target identification is a laborious 
process that is bottlenecked at several key points. The current 
reliance on generation of spontaneous drug-resistant mutants 
(DRMs) and whole genome sequencing (WGS) of single nucle-
otide polymorphisms (SNPs) and deletions is effective,20,24–26 
but has a high failure rate. In addition, not all compounds are 
suitable for the generation of DRMs as the target may be highly 
conserved and not prone to mutation(s). Additionally, it is not 
uncommon for SNPs to appear “off target” from the gene of in-
terest.27 By incorporating target-based methods into screening, 
compounds can be sifted for a specific mode of action prior to 
DRM generation and WGS. More specific biochemical assays 
can then be conducted in parallel with DRM generation and 
WGS. Figure 1 compares a more traditional DRM-driven target 
validation against the target-based screening.
Here, a method was developed to identify potential protein 
synthesis hits from compound libraries using whole-cell phe-
notypic screening as a tool. This screen in addition to other, 
recently developed,28,29 whole-cell phenotypic screening 
methods is focused on reducing the time required for mode of 
action studies into known effective targets.
2 |  MATERIALS AND METHODS
2.1 | Bacterial strains and growth conditions
M. tuberculosis H37Rv strain27 was electroporated with a kan-
amycin-resistant mycobacterial plasmid pTIC6a-mCherry30 
F I G U R E  1  Standard drug target 
validation pathway (A) and target-based 
screening pathway (B). The standard 
method of target validation uses DRM 
generation and WGS to identify targets, 
which can be time-consuming and result 
in identification of non-favorable drug 
targets. Target-based screening cuts the time 
investment to target identification and shifts 
DRM generation and WGS to a position 
where they can be conducted concurrently 
with other target validation steps
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and transformants selected on Middlebrook 7H10 media con-
taining 10% (v/v) OADC and 25 μg/mL of kanamycin at 37°C 
with 5% CO2. Single colonies were inoculated into 10 mL of 
Middlebrook 7H9 containing 10% OADC (v/v), 0.2% (v/v) 
glycerol, 0.05% (v/v) Tween-80 or Tyloxapol and 25 μg/mL 
of kanamycin, and statically cultured at 37°C with 5% CO2 for 
~7 days. The expression of mCherry gene was induced with 
the addition of 100 ng/mL of anhydrotetracycline. Growth rate 
was monitored by measuring optical density (OD) at 600 nm 
and cells were passaged to maintain a mid-log culture at OD600 
of 0.4–0.6. To prevent mutagenesis, no more than four pas-
sages were conducted before cultures were reinitiated from a 
parent glycerol stock. For all assays conducted no greater than 
2% DMSO was ever used. MICs for known protein synthesis 
inhibitors (apramycin, streptomycin, chloramphenicol, and 
hygromycin) and controls (isoniazid and ethambutol) were de-
termined in flat-clear bottom 96-well plates (Greiner, 655090). 
Isoniazid, ethambutol, chloramphenicol, and hygromycin were 
dissolved in DMSO and apramycin and streptomycin in 0.3% 
(v/v) Tween-20, in both cases 2% of the total assay volume. M. 
tuberculosis H37Rv was grown as above without kanamycin 
to OD 0.4 and diluted to 5 × 105 cells/mL. Diluted cell culture 
(90 µL), test compound (10 µL) was inoculated into each well 
up to make a final 100 μL solution. Plates were incubated for 
7 days at 37°C with 5% CO2. After incubation, 30 μL of 0.02% 
resazurin and 12 μL of 20% Tween-80 were added to each well 
and incubated for a further 24 hours and then visually observed 
to determine the compound MICs. HepG2 cytotoxicity was 
performed using HepG2 cells cultured using Eagle's minimum 
essential medium supplemented with 10% heat-inactivated fetal 
bovine serum, 1% non-essential amino acids, and 1% penicillin/
streptomycin as described previously.26
2.2 | Construction of pTIC6a-
mCherry vector
A codon-optimized variant of mCherry was purchased from 
Genscript and the full-length mCherry gene was amplified 
using the following primer pair (restriction sites underlined): 
mCherryFwd (5’-GAG GAA GCT TAT GGT GAG CA-3’) 
and mCherryRev (5′-TGT ACA AGT GAG AAT TCA TA-
3′). The PCR product was digested with HindIII and EcoRI 
and subsequently ligated into pTIC6a digested with identical 
enzymes. DNA sequencing and construct verification was 
carried out at the Eurofins DNA Ltd.
2.3 | Validation of the mCherry 
reporter screen
Known protein synthesis inhibitors (apramycin, streptomycin, 
chloramphenicol, and hygromycin) and controls (isoniazid 
and ethambutol) were dispensed into 384-well black wall 
flat-clear bottom plates (Greiner, 78109) in a dose-response 
fashion using HP Digital Dispenser. Isoniazid, ethambutol, 
chloramphenicol, and hygromycin were dissolved in DMSO 
and apramycin and streptomycin in 0.3% (v/v) Tween-20, in 
both cases 2% of the total assay volume. Mid-log phase M. 
tuberculosis H37Rv::pTIC6a-mCherry cells were pelleted by 
centrifugation at 4000 rpm for 15 minutes and then, washed 
twice with fresh Middlebrook 7H9 media to remove traces of 
kanamycin and adjusted to an OD600 of 0.4 in Middlebrook 
7H9 media without kanamycin. The culture was then split 
into two: one was left un-induced (-anhydrotetracycline) 
and the second was induced with 100 ng/mL anhydrotetra-
cycline (+anhydrotetracycline). Plate wells received cells at 
an OD600 0.4 and in a final volume of 50 μL and were incu-
bated to 37°C with 5% CO2 and left for 48 hours. Readings 
of mCherry fluorescence were taken using a PHERAstar FS 
from BMG LabTech plate reader at excitation 580 nm/emis-
sion 620  nm. After reading mCherry fluorescence, 15  μL 
of 0.02% resazurin and 6 μL of 20% Tween-80 were added 
to each well and the plates were incubated for a further 24 
hours. Plates were visually inspected for cellular viability 
based upon resazurin color change. Experiments were per-
formed in triplicate.
2.4 | Preliminary mCherry reporter screen 
using M. tuberculosis ribosome hits
The 38 compounds identified as M. tuberculosis ribosome 
inhibitors in a separate study (unpublished data, Professor 
James Sacchettini from Texas A&M University) were sol-
ubilized in 100% DMSO and automatically dispensed into 
384-well black wall flat-clear bottom plates (Greiner, 78109) 
in a dose-response fashion using an Echo Acoustic dis-
penser from Labcyte, to afford a final 0.25 µL solution. M. 
tuberculosis H37Rv::pTIC6a-mCherry cells were treated as 
described above and both +anhydrotetracycline and –anhy-
drotetracycline culture stocks of OD600 of 0.4 were dispensed 
into appropriate wells to a final volume of 50 µL. Plates were 
incubated and fluorescence of mCherry was measured as de-
scribed above. Resazurin was added to plates as above and 
fluorescence measurements were taken using plate reader 
PHERAstar FS from BMG LabTech at excitation 530/emis-
sion 590 nm.
2.5 | Combined single shot screen and dose-
response screens of GSK TB box
M. tuberculosis H37Rv::mCherry-pTIC6a cells were pre-
pared as described above. The cell suspension was then 
supplemented with 100 ng/mL of anhydrotetracycline. The 
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screening and dose-response experiments were conducted in 
384-well black wall flat-clear bottom plates (Greiner, 78109). 
The single shot screen assessed two different concentrations 
of drug, 10 μmol/L and 1 μmol/L, at a final volume of 50 μL 
in duplicate. The subsequent dose-response confirmation 
screen had a range of concentrations spanning 50 μmol/L to 
0.846 nmol/L at a final volume of 50 μL using four replicate 
plates. The compounds in both screens were dispensed into 
plates using an Echo Acoustic Dispenser by GSK. Positive 
control wells included 0.5% DMSO only, whereas negative 
control wells had 6.24 μg/mL of hygromycin, four times the 
MIC. Plates contained 50 μL of cells at an OD600 of 0.4 con-
taining anhydrotetracycline added to each well. Plates were 
read on a PHERAstar FS plate reader at excitation 580 nm/
emission 620 nm for mCherry fluorescence after 60 hours of 
incubation at 37°C with 5% CO2. Cell viability was assessed 
using resazurin as per above using a PHERAstar FS plate 
reader at excitation 530 nm/emission 590 nm.
2.6 | Z’ statistics and percentage survival 
calculation
Each plate had Z′ calculation conducted upon it using the 
equation –
where σp and σn equal the standard deviation of the positive 
and negative controls, respectively, and μp and μn equal the 
mean of the positive and negative controls. Plates with a Z 
prime of less than 0.5 were considered to have poorly sep-
arated controls and were excluded from the experiments. 
Results were then converted to percentage mCherry expres-
sion as per the equation –
where x equals the experimental value, p⋀ equals the mean of 
the positive control,s and n⋀ equals the mean of the negative 
controls.
2.7 | Broken beacon RNA polymerase assay
The broken beacon RNA polymerase assay31 uses a 5′ 
TAMRA labeled DNA oligo that hybridizes to a shorter 3’ 
BHQ2 labeled DNA oligo. When hybridized the BHQ2 ef-
fectively quenches the TAMRA fluorophore. When the hy-
bridized probes encounter complimentary RNA produced 
by RNA polymerase, the shorter BHQ2 probe dehybridizes 
and the longer RNA product and TAMRA probe hybridize. 
This removes the BHQ2 from the proximity of the TAMRA 
and the resulting increase in fluorescence can be detected. 
BHQ2 and TAMRA oligos were hybridized in a 2:1 ratio, 
8 μmol/L:4 μmol/L in a 500 μL aliquot. BHQ2 oligo (40 μL 
of 100  μmol/L), TAMRA oligo (20  μL of 100  μmol/L), 
100 μL 5× SSPE buffer, 25 μL 20× Denhardt's reagent, and 
315 μL of dH2O were added into a 1.5-mL microcentrifuge 
tube. The mixture was heated at 95°C which reduced by 10 
°C every 5 minutes. Reactions of 20 μL were set up with E. 
coli RNA Polymerase, Holoenzyme (NEB, M0551S). RNA 
polymerase buffer (5×, 4 μL), 1 μL E. coli RNA polymer-
ase, 125 μmol/L ATP, 125 μmol/L CTP, 125 μmol/L GTP, 
125 μmol/L UTP, 5 μL of hybridized TAMRA/BHQ2 oli-
gos, 40 nM of mmsA DNA template were made up to 19 μL 
with RNase free dH2O. Hits in 20% DMSO (2  mmol/L) 
were added for 100 μmol/L compound in 1% DMSO. The 
reactions were read on a BMG plate reader every 30 sec-
onds for 1000 cycles. The sequence of the TAMRA and 
BHQ2 probes are shown in Table 1. The mmsA template 
DNA was 440 base pairs long and included 179 bases pairs 
of DNA upstream of the mmsA start site to include the pro-
motor region. The primers for the PCR of the mmsA tem-
plate are shown in Table 2.
3 |  RESULTS
3.1 | Development of a phenotypic screening 
assay to identify protein synthesis hits
Target identification is a crucial step in TB drug discov-
ery, which is commonly conducted using WGS of sponta-
neous DRMs. The caveat of this process is that discovered 
targets may not be suitable or may not be the true target at 
Z� =1−
3
(
휎p+휎n
)
(
휇p−휇n
)
%mCherryExpression=
�
x−n
⋀
p
⋀
−n
⋀
�
×100
T A B L E  1  DNA sequence of broken beacon probes and location 
of attached modifications. TAMRA is excited at a wavelength of 
557 nm and emits at a wavelength of 583 nm. BHQ2 maximally 
quenches at 579 nm.
DNA Sequence 5′ – 3′ Modifications
ttcacatttcatcgacggacaacg 5′ – TAMRA
cgatgaaatgtgaa 3′ – BHQ2
T A B L E  2  Primers for mmsA template DNA.
Direction DNA Sequence 5′ – 3′
Forward catgcatgcatatgctagccatgatggagcgcag
Reverse catgcatgaagcttcagctcggccaactcgtcga
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all. To avoid these pitfalls, whole-cell phenotypic screen-
ing to search for molecules inhibiting specific targets from a 
compound library has become common place. A phenotypic 
screen utilizing mCherry fluorescence to identify hits of the 
protein synthesis pipeline was developed as there are sev-
eral key enzymes that have already been clinically validated 
as excellent targets for drug treatment within this pathway. 
The method uses anhydrotetracycline-inducible expression 
F I G U R E  2  MIC determination of known protein synthesis inhibitors and control inhibitors. Visual confirmation of drugs MICs using 
resazurin. Pink colored wells indicate cell survival. Blue wells indicate cell death. Red values in the table show the MIC for each compound
ethambutol
isoniazid media (-vecontrol)
cells only 
(+ve control
1 2 3 4 5 6 7 8 9
chloramphenicol
apramycin media (-ve
control)
cells only 
(+ve control
hygromycin
streptomycin media (-vecontrol)
cells only 
(+ve control
Con
Concentrations (μg/ml)
column number 1 2 3 4 5 6 7 8 9
isoniazid 0 0.01 0.02 0.04 0.06 0.08 0.1 0.2 0.4
ethambutol 0 0.039 0.078 0.16 0.31 0.625 1.25 2.5 5
apramycin 0 0.078 0.16 0.32 0.625 1.25 2.5 5 10
chloramphenicol 0 0.18 0.375 0.75 1.5 3 6 12 24
streptomycin 0 0.0625 0.125 0.25 0.5 1 2 4 8
hygromycin 0 0.78 1.56 3.15 6.25 12.5 25 50 100
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of the fluorescent protein mCherry as a read-out for whole-
cell protein expression. To validate this approach, several 
known inhibitors of the ribosome were used to assess drug-
mediated protein expression inhibition and therefore fluores-
cence reduction. The MICs of these drugs was determined 
and is shown in Figure 2 and Table 3. Crucial to this ap-
proach is the ability to monitor cell survival to ensure that 
the fluorescence is not reduced simply from cell death. The 
data shown in Figure 3 show that the known protein synthesis 
inhibitors—chloramphenicol, streptomycin, apramycin, and 
hygromycin—display a dose-dependent reduction in pro-
tein synthesis expression, which can be measured using the 
mCherry fluorescent protein. In addition, the cellwall syn-
thesis inhibitors—isoniazid and ethambutol—showed no de-
crease in mCherry fluorescence. Fluorescence was converted 
to percentage mCherry expression. The positive control used 
was 2% DMSO with anhydrotetracycline to induce mCherry 
expression and the negative control was without anhydrotet-
racycline to account for background leaky protein expression. 
The short incubation period resulted in a detectable reduction 
in protein synthesis without causing cellular death. To ensure 
the reduction in protein synthesis was not due to reduced cell 
viability, resazurin was used to visually assess cell survival 
after measuring mCherry fluorescence.
3.2 | Proprietary screen with M. tuberculosis 
ribosome inhibitors
Initial screening focused on a select group of 38 hits that 
targeted the ribosome (Table 4) provided by Professor 
James Sacchettini, established using a cell-free method 
(unpublished data). Of the 38 compounds, 23 showed a 
dose-dependent reduction in mCherry expression consist-
ent with protein synthesis inhibition. Importantly, resa-
zurin fluorescence showed that the decrease in mCherry 
expression across the plates was due to protein synthesis 
inhibition as indicated by decrease in mCherry expression 
and not due to a reduction in cellular survival. The data 
in Figure 4 show 10 of the compounds that displayed a 
dose response. These also include RIF and linezolid, which 
were used as controls. The compounds that failed to show 
a dose-dependent reduction in mCherry expression were 
potentially unable to pass through the mycobacterial outer 
membrane.
3.3 | Single shot high throughput 
screen results
The single shot screen, shown in Figure 5, was used as a 
tool for separating potential hits from a larger chemical 
library. The compounds screened were the TB box-set li-
brary produced by GlaxoSmithKline (GSK) of anti-tuber-
cular drugs.31,32 Single well experiments were used at two 
compound concentrations, 10 μmol/L and 1 μmol/L, and 
potential hits were designated by a percentage mCherry 
expression of less than 50% at either 10 μmol/L or at both 
10 μmol/L and 1 μmol/L. Fluorescence values were con-
verted to percentage mCherry expression, as per the vali-
dation, by subtracting the hygromycin negative control 
and normalizing against the DMSO-positive control. It 
should be noted that in Figure 5A,B at higher concentra-
tions, it may well be possible that some hits may produce 
T A B L E  3  MIC values of known inhibitors used to validate mCherry screen. These concentrations correspond to the x MIC values for Figure 
3.
MIC (μg/mL) ×0.5 ×1 ×1.25 ×1.5 ×1.75 ×2 ×2.25 ×2.5 ×3 ×3.5 ×4
Isoniazid 0.02 0.04 0.05 0.06 0.07 0.08 0.09 0.10 0.12 0.14 0.16
Ethambutol 0.63 1.25 1.56 1.88 2.19 2.5 2.81 3.13 3.75 4.38 5.00
Apramycin 0.31 0.63 0.78 0.94 1.09 1.25 1.41 1.56 1.88 2.19 2.50
Chloramphenicol 1.50 3.00 3.75 4.50 5.25 6.00 6.75 7.50 9.00 10.50 12.00
Streptomycin 0.13 0.25 0.31 0.38 0.44 0.50 0.56 0.63 0.75 0.88 1.00
Hygromycin 0.78 1.56 1.95 2.34 2.73 3.12 3.51 3.90 4.68 5.46 6.24
F I G U R E  3  The effect of known inhibitors on the percentage 
expression of mCherry. Isoniazid and ethambutol negative controls 
show no mCherry expression decrease. Known protein synthesis 
inhibitors hygromycin, chloramphenicol, streptomycin, and apramycin 
show a dose-dependent decrease in mCherry expression
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a detergent-like effect and stimulate growth. After treat-
ment with resazurin, the cells in the individual experi-
ments were checked for viability to assure a decrease in 
mCherry fluorescence was due to protein synthesis inhi-
bition and not due to cell death. Of the 2799 compounds 
screened, 91 compounds, 3.25%, were designated as hits.
3.4 | Dose-response results
Compounds identified by the single shot screen were subjected 
to a more rigorous dose-response testing to filter out any false 
positives. Using secondary dose-response screening allows the 
selection criteria in the single shot screen to be more relaxed. 
Compound Molecular Structure
A
B
C
F
K
L
U
W
T A B L E  4  Molecular structures of 
proprietary screen hits.
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This can help account for genuine hits that may normally be 
missed due to having a standardized compound concentration, 
that is, where the compound concentration is too low to show 
the desired phenotype. The range of concentrations spanned 
50 μmol/L to 0.846 nmol/L, this started higher and ended lower 
than the concentrations used in the single shot screen. The 
plates were first assessed by Z′, any plate with a Z′ lower than 
0.5 was excluded from the results. This resulted in one group of 
plates having results in triplicate instead of quadruplicate. The 
average Z′ across the whole experiment, including the excluded 
plate, was 0.626. The fluorescence values were normalized as 
described above and of the ninety one initial hits progressed, 18 
displayed a desired dose-dependent response, 10 of which are 
shown in Figure 6 and Table 5, in addition to RIF and linezolid 
included in the screen as controls. This represented 0.64% of all 
compounds screened.
3.5 | Broken beacon RNA polymerase 
assay results
To validate this screening methodology, 10 of the 18 dose-
response hit compounds were examined for activity in an 
RNA polymerase assay using commercial E. coli RNA 
polymerase. The hits were screened along with positive and 
negative control inhibitors rifampicin (RNA polymerase) 
and chloramphenicol (protein synthesis inhibitor), respec-
tively. The results of two of the hits are shown in Figure 7. 
The positive control and blank sample show good separation, 
with rifampicin knocking activity down to near blank levels 
and chloramphenicol showing negligible effect on overall 
activity. Hits 15 and 16 both show a significant reduction in 
fluorescence and therefore a reduction in the amount of RNA 
produced by RNA polymerase.
F I G U R E  4  Dose response of hit 
compounds found in the preliminary screen. 
Percentage mCherry expression displayed in 
yellow. Percentage cell survival displayed 
in blue
(A)
(C)
(E)
(G)
(I)
(B)
(D)
(F)
(H)
(J)
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4 |  DISCUSSION
Phenotypic screening of large compound libraries is the cur-
rent gold standard for the discovery of novel anti-tubercular 
agents with promising pharmacokinetic properties.32–34 Large 
screens, such as these excel at finding novel inhibitors but fall 
short when it comes to target identification. This results in a 
reliance on WGS to identify the drug targets from spontane-
ous DRMs, which can be time consuming to generate. This 
process can often be complicated by promiscuous scaffolds 
that have little in the way of target specificity,35 or targets 
that have human homologues. Incorporating some aspect of 
target identification into preliminary screening can help alle-
viate these issues and accelerate the drug discovery process. 
In this work, we have developed a mCherry reporter screen to 
identify protein synthesis hits, more specifically inhibitors of 
RNA polymerase, tRNA synthase, and the ribosome.
M. tuberculosis protein synthesis is a well-known drug-
gable pathway with some of the most potent anti-tubercular 
drugs targeting related enzymes. The rifampin class of anti-
biotics, most notably rifampicin, target RNA polymerase to 
halt the DNA to mRNA transcription.4–8 Ribosomal inhibi-
tors, such as streptomycin, prevent the translation of mRNA 
into protein.9–14 Additionally, mupirocin is a tRNA synthase 
inhibitor used topically for Staphylococcus aureus. While M. 
tuberculosis is intrinsically resistant to mupirocin,36 there are 
documented inhibitors of mycobacterial tRNA synthase.20–23 
Inhibition of tRNA synthase stops the regeneration of tRNA 
and prevents the addition of amino acids to nascent protein. 
The result of these forms of inhibition is a prevention of pro-
tein synthesis, resulting in cellular death.
The validation of the mCherry reporter assay has shown 
that cells expressing mCherry fluorescent protein subjected 
to known protein synthesis inhibitors display a dose-depen-
dent reduction of fluorescence as shown in Figure 3. The 
resazurin viability assay confirmed visually that the resulting 
reduction in fluorescence was not due to cellular death. This 
indicated that the fluorescence reduction stemmed only from 
a reduction in mCherry protein production.
The relationship between protein synthesis inhibitors and 
mCherry fluorescence has been optimized for a small-scale 
proprietary screen and focused on a set of ribosomal inhibi-
tors, previously untested against whole-cell M. tuberculosis, in 
a dose-response fashion. Two thirds of the hits showed a dose 
response consistent with patterns displayed by the known pro-
tein synthesis inhibitors during validation. In addition, quanti-
tative measurement of resazurin fluorescence showed that the 
reduction was not due to cell death, suggesting that many of 
these inhibitors are effective at inhibiting the M. tuberculosis 
ribosome, as previously suggested by cell-free assays. The ad-
vantage of using phenotypic methods, in particular with my-
cobacteria is that any hits found must be able to pass through 
the mycobacterial cell wall, meaning unsuccessful compounds 
are filtered out at an early stage of the drug discovery pipeline.
Based upon the success of the proprietary screen, the 
full GSK “TB box” was screened. This library of com-
pounds is known to be effective against M. tuberculosis. 
Initially the full library was screened with a single shot 
approach. Hits were selected based upon a reduction of 
mCherry fluorescence to 50% or lower as shown in Figure 
5 with viability confirmed using the quantitative resazurin 
assay. The 91 hits found were then progressed to dose-re-
sponse screening. Of the 91 hits, 18 displayed fluorescence 
decreases consistent with the known inhibitors used during 
validation. These 18 hits inhibit M. tuberculosis protein 
synthesis via an unknown mechanism of action and could 
potentially inhibit RNA polymerase, the ribosome or other 
involved enzymes, such as tRNA synthases.
Using an RNA polymerase assay we have shown that this 
screening method can correctly identify hits of the protein 
F I G U R E  5  Percentage expression 
results and cell survival for all 2799 
compounds screened. The red line denotes 
the cutoff threshold for positive results 
displaying lower than 50% mCherry 
expression. Panel A shows results for 
the 1 μmol/L screen, panel B shows the 
10 μmol/L screen. The left panels of each 
figure show the percentage mCherry 
expression and the right panels show the 
percentage survival as determined by 
resazurin
(A)
(B)
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synthesis pipeline from compound libraries. Hits 15 and 16 
both inhibit RNA polymerase in vitro. While they lack in po-
tency when compared to the control compound rifampicin, 
these scaffolds could be valuable with further structural mod-
ification and optimization.
Presented herein, the developed screening method uti-
lizes inducible mCherry fluorescent protein expression 
to rapidly screen compound libraries for inhibitors of the 
protein synthesis pipeline. The validation and subsequent 
screening of two sets of compounds have shown that the 
method is sensitive for selecting protein synthesis inhibi-
tors from compound libraries. These hit compounds were 
subsequently examined with an RNA polymerase assay, 
which identified two inhibitors of RNA polymerase. While 
this screen excels at finding such hits, the method offers no 
means of distinguishing the different mechanisms of action 
that result in protein synthesis inhibition and therefore must 
be coupled with target identification assays. To capitalize 
on the success of this screening method, efforts are ongo-
ing in our laboratory to develop a more robust fluorescent 
assay to test inhibitors against the ribosome to be coupled 
with the broken beacon RNA polymerase assay. We expect 
that this screen, combined with the RNA polymerase and 
ribosomal assays, can then be used to rapidly search for and 
confirm the target complex of protein synthesis inhibitors. 
In this regard, the newly developed screen can focus drug 
development efforts on narrow range of known effective 
targets.
F I G U R E  6  Dose response of hit 
compounds found in the large-scale screen. 
Percentage mCherry expression displayed in 
yellow. Percentage cell survival displayed 
in blue. Compound 2 was an additional 
blind linezolid control
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Compound Molecular Structure
HepG2 Tox50 
(μmol/L)
1 4
2 (Linezolid) 4
3 4
4 4
5 4
6 4.1
7 4
8 4
15 4.4
16 4
T A B L E  5  Molecular structures of TB 
box screen hits.
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